BRIEF—Recordati's Isturisa data published in European Journal of Endocrinology

The long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Recordati’s Isturisa (osilodrostat) have been published in The European Journal of Endocrinology.

These data support the long-term use of Isturisa in the maintenance treatment of patients with Cushing’s disease and reinforce it as an effective and well-tolerated oral therapy.

Publication of the data in the journal is a boost for Recordati’s marketing of Isturisa, which is indicated in the European Union for the treatment of adult patients with endogenous Cushing’s syndrome.